Products Atorvastatin + Atorvastatin
Atorvastatin + Atorvastatin Phase 1 Completed 💤 Quiet Interest: 29/100
Pediatric Heterozygous Hypercholesterolemia
Pediatric Heterozygous Hypercholesterolemia
Dec 1, 2008 → May 1, 2009
About Atorvastatin + Atorvastatin Atorvastatin + Atorvastatin is a phase 1 stage product being developed by Pfizer for Pediatric Heterozygous Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00739999. Target conditions include Pediatric Heterozygous Hypercholesterolemia.
What happened to similar drugs? 3 of 19 similar drugs in Pediatric Heterozygous Hypercholesterolemia were approved
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT01033058 Approved UNKNOWN Dec 1, 2009 Jun 1, 2011 STEMI NCT00739999 Phase 1 Completed Dec 1, 2008 May 1, 2009 Pediatric Heterozygous Hypercholesterolemia NCT00728988 Approved Completed Sep 1, 2008 Apr 1, 2010 Acute Coronary Syndrome NCT00917579 Approved Completed Jul 1, 2008 Sep 1, 2008 Hypercholesterolemia NCT00644670 Approved Completed Jun 1, 2003 Mar 1, 2004 Dyslipidemias
Competing Products 20 competing products in Pediatric Heterozygous Hypercholesterolemia
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3